Zobrazeno 1 - 10
of 95
pro vyhledávání: '"M V Williams"'
Autor:
Brittany B Martabano, Steven Dow, Lyndah Chow, Margaret M V Williams, Maura K Mack, Rebecca Bellone, Kathryn L Wotman
Publikováno v:
PLoS ONE, Vol 19, Iss 2, p e0297366 (2024)
ObjectiveTo determine the safety and efficacy of perilesional human recombinant interferon alpha-2b (IFNα2b) for treatment of periocular squamous cell carcinoma (PSCC) in horses.Animals studiedEleven horses (12 eyes) with PSCC were enrolled in this
Externí odkaz:
https://doaj.org/article/a40d608caf8242d7b046e27e99f9c5ee
Autor:
M. V. Williams, N. G. Burnet, E. Sherwin, R. Kestelman, A. R. Geater, S. J. Thomas, C. B. Wilson
Publikováno v:
Sarcoma, Vol 8, Iss 1, Pp 37-42 (2004)
Purpose. Following limb conserving surgery for bone or soft tissue sarcoma, patients may require post-operative radiotherapy to minimise the risk of local recurrence. In such circumstances the metal prosthesis reduces the dose in its shadow by approx
Externí odkaz:
https://doaj.org/article/65558ce2859e427f92600e45b560b296
Autor:
E. Sherwin, M. V. Williams, Charles Wilson, R. Kestelman, A. R. Geater, Neil G. Burnet, Simon J. Thomas
Publikováno v:
Sarcoma, Vol 8, Iss 1, Pp 37-42 (2004)
Sarcoma
Sarcoma
Purpose. Following limb conserving surgery for bone or soft tissue sarcoma, patients may require post-operative radiotherapy to minimise the risk of local recurrence. In such circumstances the metal prosthesis reduces the dose in its shadow by approx
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6939a87850c27cd971be964ebb3ebc9f
Autor:
Isabel Syndikus, Andrea M. Stevens, T. A. Lister, H Lucraft, David Cunningham, John Radford, Dianne Gilson, Alan Horwich, Rosie Cooke, Michael Jones, S J Harris, S Falk, Peter Hoskin, Timothy M Illidge, Barry W. Hancock, David C. Linch, M. V. Williams, Anthony J. Swerdlow
Publikováno v:
British Journal of Cancer; Vol 108
British Journal of Cancer
British Journal of Cancer
Background: Women treated with supradiaphragmatic radiotherapy (sRT) for Hodgkin lymphoma (HL) at young ages have a substantially increased breast cancer risk. Little is known about how menarcheal and reproductive factors modify this risk. Methods: W
Autor:
Isabel Syndikus, Barry W. Hancock, John Radford, H Lucraft, Andrew Bates, David Cunningham, Andrea M. Stevens, M. V. Williams, Alan Horwich, Dianne Gilson, Peter Hoskin, T. Andrew Lister, Anthony J. Swerdlow, Rosie Cooke, Stephen Falk, David C. Linch, Sarah J. Harris
Publikováno v:
Journal of Clinical Oncology; Vol 30
Purpose To investigate breast cancer risk after supradiaphragmatic radiotherapy administered to young women with Hodgkin's lymphoma (HL) in a much larger cohort than previously to provide data for patient follow-up and screening individualized accord
Autor:
T. Speroff, S. Nwosu, R. Greevy, M. B. Weinger, T. R. Talbot, R. J. Wall, J. K. Deshpande, D. J. France, E. W. Ely, H. Burgess, J. Englebright, M. V. Williams, R. S. Dittus
Publikováno v:
BMJ Quality & Safety. 19:592-596
Context Bureaucratic organisational culture is less favourable to quality improvement, whereas organisations with group (teamwork) culture are better aligned for quality improvement. Objective To determine if an organisational group culture shows bet
Publikováno v:
British Journal of Cancer
This audit was conducted to measure waiting times for systemic cancer therapy across the United Kingdom. All patients, aged 16 years or older, commencing their first course of systemic therapy between 13 November and 19 November 2006 were eligible fo
Autor:
M V Williams
Publikováno v:
The British Journal of Radiology. 80:297-301
Radiotherapy incidents involving a major overdose such as that which affected a patient in Glasgow in 2006 are rare. The publicity surrounding this patient's treatment and the subsequent publication of the enquiry by the Scottish Executive have led t
Autor:
John Graham, Graham M. Mead, P. A. Cook, M. Sokal, David P. Dearnaley, J. T. Roberts, Michael Cullen, Stan B. Kaye, Sophie D. Fosså, M. V. Williams, SP Stenning, S. J. Harland
Publikováno v:
British Journal of Cancer
Adjuvant BEP (bleomycin, etoposide, cisplatin) is effective treatment for high-risk clinical stage I (HRCS1) non-seminomatous germ cell tumours (NSGCT), but the known toxicities of etoposide, and the expansion of the HR group to any patient with vasc